AIM: To observe the growth inhibitory effect of wild-type Kras2 gene on a colonic adenocarcinoma cell line Caco-2. METHODS: Recombinant plasmid pCI-neo-Kras2 with wild type Kras2 open reading frame was constructed. The Caco-2 cells were transfected with either pCI-neo or pCI-neo-Kras2 using Lipofectamine 2000. The expression of wild type Kras2 was examined by Northern blot analysis. And the expression of wild type Kras2 protein was examined by Western blot analysis. The effects of wild-type Kras2 on cell proliferation were analyzed by monotetrazolium (MTT) assay, meanwhile analyses of cell cycle and spontaneous apoptosis rate were carried out by flow cytometry (FCM). RESULTS: The plasmid of pCI-neo-Kras2 was successfully established. The growth rate of cells transfected with pCI-neo-Kras2 was significantly lower than the control cells transfected with the empty pCI-neo vector (P<0.05). Cell cycle analysis revealed arrest of the pCI-neo-Kras2 transfected cells in G0/G1 phases, decreased DNA synthesis and decreased fractions of cells in S phase. The proliferative index of cells transfected with pCI-neo-Kras2 was decreased compared with the control cells (49.78% vs 64.21%), while the apoptotic rate of Caco-2 cells with stable Kras2 expression increased (0.30% vs 0.02%). CONCLUSION: The wild-type Kras2 gene effectively inhibits the growth of the colonic adenocarcinoma cell line Caco-2.
AIM: To observe the growth inhibitory effect of wild-type Kras2 gene on a colonic adenocarcinoma cell line Caco-2. METHODS: Recombinant plasmid pCI-neo-Kras2 with wild type Kras2 open reading frame was constructed. The Caco-2 cells were transfected with either pCI-neo or pCI-neo-Kras2 using Lipofectamine 2000. The expression of wild type Kras2 was examined by Northern blot analysis. And the expression of wild type Kras2 protein was examined by Western blot analysis. The effects of wild-type Kras2 on cell proliferation were analyzed by monotetrazolium (MTT) assay, meanwhile analyses of cell cycle and spontaneous apoptosis rate were carried out by flow cytometry (FCM). RESULTS: The plasmid of pCI-neo-Kras2 was successfully established. The growth rate of cells transfected with pCI-neo-Kras2 was significantly lower than the control cells transfected with the empty pCI-neo vector (P<0.05). Cell cycle analysis revealed arrest of the pCI-neo-Kras2 transfected cells in G0/G1 phases, decreased DNA synthesis and decreased fractions of cells in S phase. The proliferative index of cells transfected with pCI-neo-Kras2 was decreased compared with the control cells (49.78% vs 64.21%), while the apoptotic rate of Caco-2 cells with stable Kras2 expression increased (0.30% vs 0.02%). CONCLUSION: The wild-type Kras2 gene effectively inhibits the growth of the colonic adenocarcinoma cell line Caco-2.
Authors: D Shibata; C Almoguera; K Forrester; J Dunitz; S E Martin; M M Cosgrove; M Perucho; N Arnheim Journal: Cancer Res Date: 1990-02-15 Impact factor: 12.701
Authors: S Rodenhuis; R J Slebos; A J Boot; S G Evers; W J Mooi; S S Wagenaar; P C van Bodegom; J L Bos Journal: Cancer Res Date: 1988-10-15 Impact factor: 12.701
Authors: B Vogelstein; E R Fearon; S R Hamilton; S E Kern; A C Preisinger; M Leppert; Y Nakamura; R White; A M Smits; J L Bos Journal: N Engl J Med Date: 1988-09-01 Impact factor: 91.245
Authors: Jie Li; Zhongqiu Zhang; Zunyan Dai; Christoph Plass; Carl Morrison; Yian Wang; Jonathan S Wiest; Marshall W Anderson; Ming You Journal: Oncogene Date: 2003-02-27 Impact factor: 9.867
Authors: J P Perentesis; S Bhatia; E Boyle; Y Shao; X Ou Shu; M Steinbuch; H N Sather; P Gaynon; W Kiffmeyer; J Envall-Fox; L L Robison Journal: Leukemia Date: 2004-04 Impact factor: 11.528
Authors: Roberto Diaz; Daniel Ahn; Lluis Lopez-Barcons; Marcos Malumbres; Ignacio Perez de Castro; Jeffrey Lue; Neus Ferrer-Miralles; Ramon Mangues; Jerry Tsong; Roberto Garcia; Roman Perez-Soler; Angel Pellicer Journal: Cancer Res Date: 2002-08-01 Impact factor: 12.701
Authors: Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal Journal: Nature Date: 2002-06-09 Impact factor: 49.962
Authors: Chih-Chieh Yu; Wanglong Qiu; Caroline S Juang; Mahesh M Mansukhani; Balazs Halmos; Gloria H Su Journal: Cancer Lett Date: 2016-10-08 Impact factor: 8.679
Authors: Wanglong Qiu; Fikret Sahin; Christine A Iacobuzio-Donahue; Dario Garcia-Carracedo; Wendy M Wang; Chia-Yu Kuo; Doris Chen; Dan E Arking; Andrew M Lowy; Ralph H Hruban; Helen E Remotti; Gloria H Su Journal: Oncotarget Date: 2011-11